Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity
July 07, 2010
Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity
Pharmacogenomics Reporter took stock of industry expectations ahead of FDA's upcoming meeting to discuss the agency's strategy for regulating laboratory-developed tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Clarient's Mammostrat to Enter Breast Cancer Recurrence Market as LDT by Fourth Quarter
July 14, 2010 / Pharmacogenomics Reporter - FDA Shelves IVDMIA Final Guidelines in Order to Focus on Overall LDT Regulation
June 23, 2010 / Pharmacogenomics Reporter - 2010 in Review: Genomic Medicine Experiences Growing Pains of Regulation, Economics, and Litigation
January 12, 2011 / Pharmacogenomics Reporter - DTC Genomics Gets Time Before FDA as Agency Considers Regulatory Strategy
July 21, 2010 / Pharmacogenomics Reporter - FDA's Gutierrez Provides Additional Clarity Regarding Oversight of DTC Genomics Firms
May 19, 2010 / Pharmacogenomics Reporter